✦ LIBER ✦

Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group

✍ Scribed by Meral Beksac; Rauf Haznedar; Tulin Firatli-Tuglular; Hakan Ozdogu; Ismet Aydogdu; Nahide Konuk; Gulsan Sucak; Işık Kaygusuz; Sema Karakus; Emin Kaya; Ridvan Ali; Zafer Gulbas; Gulsum Ozet; Hakan Goker; Levent Undar

Book ID: 114794847
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 186 KB
Volume: 86
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2010.01524.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alternating combination chemotherapy (VM

Alternating combination chemotherapy (VMCP/VBAP) is not superior to melphalan/prednisone in the treatment of multiple myeloma patients stage III —A randomized study from MGCS

✍ A. Österborg; A. Ahre; M. Björkholm; M. Björeman; G. Brenning; G. Gahrton; H. Gy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB

A prospective, randomized study of cryot

A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation

✍ Maloney, D G; Press, O W; Bensinger, W; Lilleby, K; Garcia, P; Gooley, T; McDonn 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 115 KB

Treatment of Bendamustine and Prednisone

Treatment of Bendamustine and Prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with Melphalan and Prednisone—a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO)

✍ W. Pönisch; P. S. Mitrou; K. Merkle; M. Herold; M. Assmann; G. Wilhelm; K. Dachs 📂 Article 📅 2006 🏛 Springer-Verlag 🌐 English ⚖ 344 KB

High-dose idarubicin, cyclophosphamide a

High-dose idarubicin, cyclophosphamide and melphalan as conditioning for autologous stem cell transplantation increases treatment-related mortality in patients with multiple myeloma: results of a randomised study

✍ R. Fenk; P. Schneider; M. Kropff; A. N. Huenerlituerkoglu; U. Steidl; C. Aul; B. 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB